ESC 365 - Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort

ESC Professional Premium Access

Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort

Session: Hypertrophic cardiomyopathy: not so rare, but not so easy

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor M. Brandao (Vila Nova de Gaia, PT)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Mariana Brandao

Hospital Center of Vila Nova de Gaia/Espinho, Vila Nova de Gaia (Portugal)

7 presentations

1 follower

4 more presentations in this session

Metoprolol improves left ventricular longitudinal function at rest and during exercise in obstructive hypertrophic cardiomyopathy

Speaker: Mrs A. Dybro (Aarhus, DK)

Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis

Speaker: Doctor I. Olivotto (Florence, IT)

Prevalence and clinical correlates of clinical red flags for rare diseases in consecutive patients presenting with HCM phenotype

Speaker: Doctor N. Maurizi (Lausanne, CH)

Temporal trends, characteristics and comorbidities of patients with hypertrophic cardiomyopathy in denmark from 2005-2018: A nationwide cohort study.

Speaker: Doctor C. Zoerner (Copenhagen, DK)

Access the full session

Hypertrophic cardiomyopathy: not so rare, but not so easy

Speakers: Doctor M. Brandao, Mrs A. Dybro, Doctor I. Olivotto, Doctor N. Maurizi, Doctor C. Zoerner

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources